Promab Biotechnologies

Executive Summary

Promab Biotechnologies is a US-based contract research and development organization (CRO/CDMO) specializing in custom antibody production, cell therapy development, and mRNA-LNP delivery services. Founded in 2001, the company provides integrated services from early discovery through clinical trials, leveraging its expertise in antibody engineering, CAR-T/NK cell development, and lipid nanoparticle formulation. Its mission is to support partners in advancing novel therapeutic candidates, particularly in oncology and immunotherapy. With a strong foothold in the biotech services sector, Promab serves a diverse client base ranging from small biotechs to large pharmaceutical companies, enabling them to accelerate their development timelines.

Upcoming Catalysts (preview)

• Q3 2026Launch of proprietary CAR-NK platform service60% success
• H2 2026Strategic partnership with top-20 pharma for mRNA-LNP manufacturing50% success
• Q4 2026Expansion of Richmond facility to double production capacity70% success